Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Nobels väg 12A, 17165 Solna, Stockholm, Sweden.
Department of Psychiatry, Warneford Hospital, University of Oxford, Oxford, United Kingdom.
Eur Neuropsychopharmacol. 2020 Jul;36:1-9. doi: 10.1016/j.euroneuro.2020.03.024. Epub 2020 May 29.
This study identified individuals ever dispensed a selective serotonin reuptake inhibitor (SSRI) aged 15-60 years during 2006-2013, using Swedish national registers. The outcome was violent crime conviction. The main statistical analyses assessed risks of violent crime during periods on compared to off SSRI treatment within individuals. Further analyses investigated risk over time in relation to treatment initiation and discontinuation. The study identified 785,337 individuals (64.2% female), experiencing 32,203 violent crimes in 5,707,293 person-years. Between-individual analyses found statistically significantly elevated Hazard Ratios (HRs) overall (HR = 1.10), and in 15-24 and 25-34 year-olds (HR = 1.19 and 1.16), but non-significant HRs in 35-44 and 45-60-year-olds (HR = 1.02 and 1.04). In within-individual analyses, where 2.6% of SSRI users were informative, hazards were elevated overall (HR = 1.26, 95% CI = 1.19, 1.34), and across age groups (HR of 1.35 [95% CI = 1.19, 1.54] in 25-34-year-olds to 1.15 [95% CI = 0.99, 1.33] in 35-44-year-olds). In the overall cohort, the within-individual HRs were significantly elevated throughout treatment (HRs of 1.24 to 1.35) and for up to 12 weeks post-discontinuation (HRs of 1.37 and 1.20). While questions on causality remain, these results indicate that there may be an increased risk of violent crime during SSRI treatment in a small group of individuals. It may persist throughout medicated periods, across age groups, and after treatment discontinuation. Further confirmation is needed from studies with different designs, and clinical focus should be on high-risk individuals, as a majority of SSRI-users (around 97% in our cohort) will not commit violent crimes.
本研究利用瑞典国家登记处,确定了在 2006 年至 2013 年间,年龄在 15-60 岁之间的曾被处方选择性 5-羟色胺再摄取抑制剂(SSRIs)的个体。结果是暴力犯罪定罪。主要统计分析评估了个体中 SSRI 治疗期间与治疗期间相比发生暴力犯罪的风险。进一步的分析调查了与治疗开始和停止相关的随时间的风险。该研究确定了 785337 名个体(64.2%为女性),在 5707293 人年中经历了 32203 起暴力犯罪。个体间分析发现总体上(HR=1.10)和 15-24 岁和 25-34 岁(HR=1.19 和 1.16)的危险比(HR)显著升高,但 35-44 岁和 45-60 岁的 HR 无统计学意义(HR=1.02 和 1.04)。在个体内分析中,2.6%的 SSRI 使用者提供了信息,总体危险升高(HR=1.26,95%CI=1.19,1.34),且跨越年龄组(25-34 岁的 HR 为 1.35 [95%CI=1.19,1.54]至 35-44 岁的 HR 为 1.15 [95%CI=0.99,1.33])。在整个队列中,个体内 HR 在整个治疗期间(HRs 为 1.24 至 1.35)和停药后最多 12 周时(HRs 为 1.37 和 1.20)均显著升高。虽然因果关系仍存在疑问,但这些结果表明,在一小部分个体中,SSRIs 治疗期间可能存在暴力犯罪风险增加。它可能在整个治疗期间持续存在,跨越年龄组,并且在治疗停止后持续存在。需要来自具有不同设计的研究进一步证实,并且临床重点应放在高风险个体上,因为大多数 SSRIs 使用者(我们队列中的约 97%)不会犯下暴力犯罪。